- Others
- Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
-
Jae-Seung Yun, Kyuho Kim, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko
-
Diabetes Metab J. 2024;48(4):531-545. Published online July 26, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0310
-
-
Abstract
PDFPubReader ePub
- Due to increased life expectancy and lifestyle changes, the prevalence of diabetes among the elderly in Korea is continuously rising, as is the associated public health burden. Diabetes management in elderly patients is complicated by age-related physiological changes, sarcopenia characterized by loss of muscle mass and function, comorbidities, and varying levels of functional, cognitive, and mobility abilities that lead to frailty. Moreover, elderly patients with diabetes frequently face multiple chronic conditions that elevate their risk of cardiovascular diseases, cancer, and mortality; they are also prone to complications such as hyperglycemic hyperosmolar state, diabetic ketoacidosis, and severe hypoglycemia. This review examines the characteristics of and management approaches for diabetes in the elderly, and advocates for a comprehensive yet personalized strategy.
- Others
- Glucose Regulation after Partial Pancreatectomy: A Comparison of Pancreaticoduodenectomy and Distal Pancreatectomy in the Short and Long Term
-
Jun Suh Lee, Minji Sohn, Kyuho Kim, Yoo-Seok Yoon, Soo Lim
-
Diabetes Metab J. 2023;47(5):703-714. Published online June 22, 2023
-
DOI: https://doi.org/10.4093/dmj.2022.0205
-
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Long term quality of life is becoming increasingly crucial as survival following partial pancreatectomy rises. The purpose of this study was to investigate the difference in glucose dysregulation after pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
Methods In this prospective observational study from 2015 to 2018, 224 patients who underwent partial pancreatectomy were selected: 152 (67.9%) received PD and 72 (32.1%) received DP. Comprehensive assessment for glucose regulation, including a 75 g oral glucose tolerance test was conducted preoperatively, and 1, 12, and 52 weeks after surgery. Patients were further monitored up to 3 years to investigate development of new-onset diabetes mellitus (NODM) in patients without diabetes mellitus (DM) at baseline or worsening of glucose regulation (≥1% increase in glycosylated hemoglobin [HbA1c]) in those with preexisting DM.
Results The disposition index, an integrated measure of β-cell function, decreased 1 week after surgery in both groups, but it increased more than baseline level in the PD group while its decreased level was maintained in the DP group, resulting in a between-group difference at the 1-year examination (P<0.001). During follow-up, the DP group showed higher incidence of NODM and worsening of glucose regulation than the PD group with hazard ratio (HR) 4.29 (95% confidence interval [CI], 1.49 to 12.3) and HR 2.15 (95% CI, 1.09 to 4.24), respectively, in the multivariate analysis including dynamic glycemic excursion profile. In the DP procedure, distal DP and spleen preservation were associated with better glucose regulation. DP had a stronger association with glucose dysregulation than PD.
Conclusion Proactive surveillance of glucose dysregulation is advised, particularly for patients who receive DP.
- Guideline/Fact Sheet
- Diabetes Mellitus in the Elderly Adults in Korea: Based on Data from the Korea National Health and Nutrition Examination Survey 2019 to 2020
-
Seung-Hyun Ko, Kyung Do Han, Yong-Moon Park, Jae-Seung Yun, Kyuho Kim, Jae-Hyun Bae, Hyuk-Sang Kwon, Nan-Hee Kim
-
Diabetes Metab J. 2023;47(5):643-652. Published online August 7, 2023
-
DOI: https://doi.org/10.4093/dmj.2023.0041
-
-
4,584
View
-
292
Download
-
10
Web of Science
-
12
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
We evaluated the prevalence and management of diabetes mellitus (DM) in elderly Korean patients based on data from the Korea National Health and Nutrition Examination Survey (KNHANES).
Methods A total of 3,068 adults aged 65 years and older (19.8% of total population) were analyzed using KNHANES from 2019 to 2020. Prevalence, awareness, treatment, and control rates, and comorbidities were analyzed. Lifestyle behaviors and energy intake were also measured.
Results The prevalence of DM and prediabetes was 29.6% and 50.5%, respectively. The awareness, treatment and control rates were 76.4%, 73.3%, and 28.3%, respectively. The control rate was 77.0% if A1C <7.5% criteria was used. The mean A1C value of individuals with known DM was 7.1%, and 14.5% of the known DM patients had A1C ≥8.0%. Abdominal obesity, hypertension, and hypercholesterolemia were combined with DM in 63.9%, 71.7%, and 70.7%, respectively, and the rate of integrated management was 36.0% (A1C <7.5% criteria). A total of 40.1% of those with DM walked regularly. The percentage of energy intake from carbohydrates was higher in those with DM than in those without DM (P=0.044), while those of fat (P=0.003) and protein (P=0.025) were lower in those with DM than in those without DM in women.
Conclusion In 2019 to 2020, three of 10 adults aged 65 years and older in Korea had DM, and approximately 70% of them had comorbidities. A strategy for more individualized comprehensive care for the elderly patients with DM is urgently needed.
-
Citations
Citations to this article as recorded by
- Association Between High Blood Folate Levels and Glaucoma in a Representative Korean Population
Ji Young Lee, Jin A. Choi, Sung Pyo Park, Donghyun Jee Investigative Opthalmology & Visual Science.2024; 65(1): 6. CrossRef - Is the change in longitudinal cognitive function in older adults with diabetes affected by trajectory classes of depressive symptoms?
Gyeong A Kang, Ju Young Yoon Public Health Nursing.2024; 41(5): 1006. CrossRef - Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
Jae-Seung Yun, Kyuho Kim, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko Diabetes & Metabolism Journal.2024; 48(4): 531. CrossRef - Association and interaction effect of shift work and the risk for obstructive sleep apnea on diabetes mellitus in middle-aged Korean workers
Kyusung Kim, Hi-Ju Kim, Seunghyun Lee, Wanhyung Lee Sleep and Breathing.2024; 28(6): 2721. CrossRef - Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim Diabetes & Metabolism Journal.2024; 48(5): 837. CrossRef - National trends in type 2 diabetes mellitus stratified by central adiposity using waist-to-height ratio in South Korea, 2005–2022
Hyunjee Kim, Seoyoung Park, Jaeyu Park, Yejun Son, Soeun Kim, Yesol Yim, Hyesu Jo, Kyeongmin Lee, Yi Deun Jeong, Jiyeon Oh, Hanseul Cho, Damiano Pizzol, Jiyoung Hwang, Lee Smith, Dong Keon Yon Scientific Reports.2024;[Epub] CrossRef - Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures
Kyoung Hwa Ha, Dae Jung Kim Endocrinology and Metabolism.2024; 39(5): 669. CrossRef - Osteoporosis incidence and its associated factors in the older Korean population: findings from a population-based cohort study
Tanmoy Das, Md Abdullah Al Jubayer Biswas, Prosanta Mondal, Sabuj Sarker, Hyun J.“June” Lim Archives of Osteoporosis.2024;[Epub] CrossRef - Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study
Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park Diabetes & Metabolism Journal.2024; 48(6): 1105. CrossRef - Socioeconomic inequalities in the prevalence, non-awareness, non-treatment, and non-control of diabetes among South Korean adults in 2021
Seongju Kim, Dong Jun Kim, Hooyeon Lee, Dong Keon Yon PLOS ONE.2024; 19(11): e0313988. CrossRef - Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim Journal of Diabetes Investigation.2024;[Epub] CrossRef - The Growing Challenge of Diabetes Management in an Aging Society
Seung-Hwan Lee Diabetes & Metabolism Journal.2023; 47(5): 630. CrossRef
- Technology/Device
- Glucose Profiles Assessed by Intermittently Scanned Continuous Glucose Monitoring System during the Perioperative Period of Metabolic Surgery
-
Kyuho Kim, Sung Hee Choi, Hak Chul Jang, Young Suk Park, Tae Jung Oh
-
Diabetes Metab J. 2022;46(5):713-721. Published online January 24, 2022
-
DOI: https://doi.org/10.4093/dmj.2021.0164
-
-
6,325
View
-
356
Download
-
5
Web of Science
-
5
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Continuous glucose monitoring (CGM) has been widely used in the management of diabetes. However, the usefulness and detailed data during perioperative status were not well studied. In this study, we described the immediate changes of glucose profiles after metabolic surgery using intermittently scanned CGM (isCGM) in individuals with type 2 diabetes mellitus (T2DM).
Methods This was a prospective, single-center, single-arm study including 20 participants with T2DM. The isCGM (FreeStyle Libre CGM) implantation was performed within 2 weeks before surgery. We compared CGM metrics of 3 days before surgery and 3 days after surgery, and performed the correlation analyses with clinical variables.
Results The mean glucose significantly decreased after surgery (147.0±40.4 to 95.5±17.1 mg/dL, P<0.001). Time in range (TIR; 70 to 180 mg/dL) did not significantly change after surgery in total. However, it was significantly increased in a subgroup of individuals with glycosylated hemoglobin (HbA1c) ≥8.0%. Time above range (>250 or 180 mg/dL) was significantly decreased in total. In contrast, time below range (<70 or 54 mg/dL) was significantly increased in total and especially in a subgroup of individuals with HbA1c <8.0% after surgery. The coefficient of variation significantly decreased after surgery. Higher baseline HbA1c was correlated with greater improvement in TIR (rho=0.607, P=0.005).
Conclusion The isCGM identified improvement of mean glucose and glycemic variability, and increase of hypoglycemia after metabolic surgery, but TIR was not significantly changed after surgery. We detected an increase of TIR only in individuals with HbA1c ≥8.0%.
-
Citations
Citations to this article as recorded by
- Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef - Continuous Glucose Monitoring Captures Glycemic Variability After Roux-en-Y Gastric Bypass in Patients with and Without Type 2 Diabetes Mellitus: A Prospective Cohort Study
Raquel do A. P. Quevedo, Maria Edna de Melo, Cintia Cercato, Ariana E. Fernandes, Anna Carolina B. Dantas, Marco Aurélio Santo, Denis Pajecki, Marcio C. Mancini Obesity Surgery.2024; 34(8): 2789. CrossRef - Perioperative Management of Adult Patients with Diabetes Wearing Devices: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Expert Consensus Statement
Adriana D. Oprea, Smita K. Kalra, Elizabeth W. Duggan, Linda L. Russell, Richard D. Urman, Basem B. Abdelmalak, Preethi Patel, Kurt J. Pfeifer, Paul J. Grant, Marina M. Charitou, Carlos E. Mendez, Jennifer L. Sherr, Guillermo E. Umpierrez, David C. Klonof Journal of Clinical Anesthesia.2024; 99: 111627. CrossRef - Use of Continuous Glucose Monitoring in Patients Following Bariatric Surgery: A Scoping Review
Yang Yu, Susan W. Groth Obesity Surgery.2023; 33(8): 2573. CrossRef - Asymptomatic Hypoglycemia after Metabolic Surgery: New Insights from Perioperative Continuous Glucose Monitoring
Sang-Man Jin Diabetes & Metabolism Journal.2022; 46(5): 675. CrossRef
- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
-
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
-
Diabetes Metab J. 2022;46(5):817-818. Published online September 19, 2022
-
DOI: https://doi.org/10.4093/dmj.2022.0295
-
Corrects: Diabetes Metab J 2022;46(4):517
-
2,932
View
-
168
Download
-
6
Web of Science
-
6
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
François Mach, Frank L.J. Visseren, Nilo B. Cater, Nejoua Salhi, Jarkko Soronen, Kausik K. Ray, Victoria Delgado, J. Wouter Jukema, Ulrich Laufs, Jose-Luis Zamorano, Emilio Ros, Jogchum Plat, Akos Gabor Gesztes, Lale Tokgozoglu, Chris Packard, Peter Libby Journal of Clinical Lipidology.2024; 18(5): e685. CrossRef - Engineered exosomes as a prospective therapy for diabetic foot ulcers
Lifei Guo, Dan Xiao, Helin Xing, Guodong Yang, Xuekang Yang Burns & Trauma.2024;[Epub] CrossRef - Lipidomic profiling in patients with familial hypercholesterolemia: Abnormalities in glycerolipids and oxysterols
Shiva Ganjali, Vladimiro Cardenia, Ambra Bonciolini, Raul D. Santos, Khalid Al-Rasadi, Amirhossein Sahebkar Clinical Biochemistry.2024; 131-132: 110812. CrossRef - Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
Gbolahan Olatunji, Ikponmwosa Jude Ogieuhi, Emmanuel Kokori, Ajekiigbe Victor Oluwatomiwa, Oluwafemi Isaiah Ajimotokan, God-dowell O. Odukudu, Samuel Owolabi, Sopuruchukwu Anyacho, Chijindu Nnaemeka Nwakama, Adetola Emmanuel Babalola, Franklin Andibanbang High Blood Pressure & Cardiovascular Prevention.2024; 31(6): 567. CrossRef - The Effect of Statin Therapy on Bone Metabolism Markers and Mineral Density: Aa GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials
Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Ali Jafari, Hossein Bahari, Željko Reiner, Amirhossein Sahebkar Advanced Pharmaceutical Bulletin.2024; 14(3): 591. CrossRef - Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review
Xiang Chen, Li-Hua Li Cureus.2023;[Epub] CrossRef
- Drug/Regimen
- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
-
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
-
Diabetes Metab J. 2022;46(4):517-532. Published online July 27, 2022
-
DOI: https://doi.org/10.4093/dmj.2022.0198
-
Correction in: Diabetes Metab J 2022;46(5):817
-
13,745
View
-
997
Download
-
39
Web of Science
-
39
Crossref
-
Abstract
PDFPubReader ePub
- Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.
-
Citations
Citations to this article as recorded by
- The role of adherence in patients with chronic diseases
Michel Burnier European Journal of Internal Medicine.2024; 119: 1. CrossRef - Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu Frontiers in Endocrinology.2024;[Epub] CrossRef - Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Monika I. Konaklieva, Balbina J. Plotkin Frontiers in Molecular Biosciences.2024;[Epub] CrossRef - Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis Journal of Cardiovascular Development and Disease.2024; 11(3): 72. CrossRef - Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar Heliyon.2024; 10(7): e28837. CrossRef - Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660. CrossRef - Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao Journal of Translational Medicine.2024;[Epub] CrossRef - Hypercholesterolemia: A literature review on management using tafolecimab – a novel member of PCSK9 monoclonal antibodies
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio Annals of Medicine & Surgery.2024;[Epub] CrossRef - Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović Galenika Medical Journal.2024; 3(9): 31. CrossRef - Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee Endocrinology and Metabolism.2024; 39(3): 511. CrossRef - Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal Pharmacy.2024; 12(4): 104. CrossRef - Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
Jan Schjøtt, Kristine Heitmann European Journal of Cardiovascular Nursing.2024;[Epub] CrossRef - CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li Scientific Reports.2024;[Epub] CrossRef - Lessons from PROMINENT and prospects for pemafibrate
Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon Cardiovascular Diabetology.2024;[Epub] CrossRef - A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
Qianqian Xiao, Luyun Wang, Jing Wang, Man Wang, Dao Wen Wang, Hu Ding Molecular Metabolism.2024; 88: 102011. CrossRef - Advances in pharmacotherapy of dyslipidemia
Harshitha Chinta National Journal of Pharmacology and Therapeutics.2024; 2(2): 68. CrossRef - ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Jingfei Chen, Qin Luo, Yanfeng Yi, Jiangang Wang, Pengfei Chen, Fei Luo, Zhenfei Fang Lipids in Health and Disease.2024;[Epub] CrossRef - Assessing the effects of HMGCR, LPL, and PCSK9 inhibition on sleep apnea: Mendelian randomization analysis of drug targets
Wei Tan, Xiujuan Deng, Xiaoning Tan, Guangbo Tan Medicine.2024; 103(43): e40194. CrossRef - Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study
Lei Zhong, Bo Xie, Hai-Li Wang, Xiao-Wei Ji Scientific Reports.2024;[Epub] CrossRef - A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction
Jing-Hui Wang, Guan-Rui Pan, Long Jiang Frontiers in Immunology.2024;[Epub] CrossRef - Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
Beibei Hou, Linhui Qin, Linfeng Huang Biochemical and Biophysical Research Communications.2023; 644: 85. CrossRef - Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
C. M. Schooling, J. V. Zhao Current Cardiology Reports.2023; 25(2): 67. CrossRef - Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi Food Science & Nutrition.2023; 11(6): 2620. CrossRef - Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206. CrossRef - Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos Journal of the American Heart Association.2023;[Epub] CrossRef - The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng Frontiers in Physiology.2023;[Epub] CrossRef - Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Alejandro Gugliucci Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef - Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206. CrossRef - Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis Pharmacy.2023; 11(4): 130. CrossRef - Advances in Treatment of Dyslipidemia
Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk International Journal of Molecular Sciences.2023; 24(17): 13288. CrossRef - Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos Biomedicines.2023; 11(10): 2696. CrossRef - Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li Scientific Reports.2023;[Epub] CrossRef - Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung Current Oncology.2023; 30(9): 8386. CrossRef - Riesgo residual. Conclusiones
Ángel Cequier, José Luis Zamorano Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef - Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen Frontiers in Endocrinology.2023;[Epub] CrossRef - Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li Journal of Health, Population and Nutrition.2023;[Epub] CrossRef - Bempedoic acid: new evidence and recommendations on use
Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach Current Opinion in Lipidology.2023;[Epub] CrossRef - Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran Biology.2022; 11(9): 1308. CrossRef - Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi Endocrinology and Metabolism.2022; 37(4): 575. CrossRef
- Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide-Cohort Study (Diabetes Metab J 2020;44:737-46)
-
Kyuho Kim, Tae Jung Oh
-
Diabetes Metab J. 2020;44(6):938-939. Published online December 23, 2020
-
DOI: https://doi.org/10.4093/dmj.2020.0236
-
-
4,295
View
-
78
Download
-
1
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- Increased Age of Death and Change in Causes of Death Among Persons With Diabetes Mellitus From the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee SSRN Electronic Journal .2020;[Epub] CrossRef
|